,149 Similarly, AAV-AADC therapy, approved by the FDA for AADC deficiency, has also been explored for Parkinson’s disease to restore dopamine synthesis, as evidenced by completed clinical trials150,151 and an ongoing clinical trial (NCT03562494). Here, DDC is linked to aromatic L-amino acid decarboxylase deficiency.